TTR and amyloidosis: miRNA delivery to the liver is relatively straightforward—for example Patisiran, an siRNA that silences transthyretin in hereditary transthyretin-mediated amyloidosis, is directly delivered to the liver and is the first Food and Drug Administration–approved RNA-based therapy (Heras-Palou, 2019).